Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes-Reference-Cited by-同舟云学术

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

Published:2011-06 Issue:12 Volume:21 Page:3809-3812
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Kim Heung Jae,Kwak Woo Young,Min Jong Pil,Lee Jae Young,Yoon Tae Hyun,Kim Ha Dong,Shin Chang Yell,Kim Mi Kyung,Choi Song Hyen,Kim Hae Sun,Yang Eun Kyoung,Cheong Ye Hwang,Chae Yu Na,Park Kyung Jin,Jang Ji Myun,Choi Soo Jung,Son Moon Ho,Kim Soon Hoe,Yoo Moohi,Lee Bong Jin

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference19 articles.

1. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

2. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

3. Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes

4. Endocrine Regulation of Human Fetal Growth: The Role of the Mother, Placenta, and Fetus

5. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling;Biomedicine & Pharmacotherapy;2023-10

2. Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants;Journal of Medicinal Chemistry;2023-08-30

3. Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers;Clinical and Translational Science;2023-06-21

4. Local anaesthetic procaine derivatives protect rat against diabetic nephropathy via inhibition of DPP‐4, inflammation and oxidative stress;Chemical Biology & Drug Design;2023-04-19

5. Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin;Diabetes, Obesity and Metabolism;2023-04-03